rsv lid deltam2-2 1030s vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02794870)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rsv lid deltam2-2 1030s vaccine
- rsv lid δm2-2 1030s vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02952339 | Phase 1 | Aug 1, 2016 | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02794870 | Phase 1 | Jun 1, 2016 | National Institute of Allergy and Infectious Diseases (NIAID), University of Colorado |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2016 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Colorado | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1